Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Down 63.1% in December

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 83,700 shares, a decline of 63.1% from the November 30th total of 226,700 shares. Based on an average daily trading volume, of 449,700 shares, the short-interest ratio is presently 0.2 days. Currently, 0.5% of the company’s stock are sold short.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the quarter. National Bank of Canada FI owned about 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $0.50. 102,452 shares of the company were exchanged, compared to its average volume of 206,709. Sensei Biotherapeutics has a 12-month low of $0.38 and a 12-month high of $1.94. The business has a fifty day moving average of $0.51 and a 200 day moving average of $0.57. The firm has a market cap of $12.47 million, a P/E ratio of -0.42 and a beta of 0.16.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.